WCN25-2522 ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN by Jonathan Barratt, Robert Brenner, Kerry Cooper, Xuelian Wei, Richard Lafayette

Get full text

WCN24-1197 EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY by Jonathan Barratt, Miguel Ángel Pérez Valdivia, Dario Roccatello, Katherine Garlo, Kara Rice, Richard Lafayette

Get full text

WCN24-1163 TREATMENT GOALS FROM THE PERSPECTIVE OF IMMUNOGLOBULIN A NEPHROPATHY PATIENTS - RESULTS FROM A REAL-WORLD STUDY by Aneesh Thomas George, Richard Lafayette, Sydney Tang, Serge Smeets, Carolina Aldworth, Raymond Przybysz, Emma Chatterton

Get full text

WCN24-1158 REAL-WORLD ANALYSIS OF PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY – DIAGNOSIS AND DISEASE MONITORING by Serge Smeets, Richard Lafayette, Sydney Tang, Carolina Aldworth, Raymond Przybysz, Aneesh Thomas George, Jade Garratt-Wheeldon

Get full text

WCN24-1159 TREATMENT PATTERNS IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY - EVIDENCE FROM REAL-WORLD DATA by Serge Smeets, Richard Lafayette, Sydney Tang, Carolina Aldworth, Raymond Przybysz, Aneesh Thomas George, Jonathan de Courcy

Get full text

WCN24-342 ATACICEPT IN IGA NEPHROPATHY: CONTINUED PROTECTIVE TITERS TO DIPHTHERIA AND TETANUS AND BALANCED INFECTIONS VS PLACEBO WITH A FOCUS ON COVID-19 by Jonathan Barratt, Bart Maes, Rubeen Israni, Xuelian Wei, Vladimir Tesar, Gerald Appel, Yusuke Suzuki, Celia Lin, Richard Lafayette

Get full text

WCN24-1680 PREVALENCE AND CLINICAL CHARACTERISTICS OF KIDNEY TRANSPLANTS IN COMPLEMENT 3 GLOMERULOPATHY PATIENTS: RESULTS FROM A REAL-WORLD, MULTI-COUNTRY SURVEY by Richard Lafayette, Raisa Sidhu, Clare Proudfoot, Katharina Pannagl, Briana Ndife, Serge Smeets, Kathleen Murphy, Raymond Przybysz, Jonathan de Courcy, Susanna Libby, Smeeta Sinha

Get full text

WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY by Jonathan Barratt, Bart Maes, Celia Lin, Xuelian Wei, Sean Barbour, Richard Phoon, Sung Gyun Kim, Vladimir Tesar, Jürgen Floege, Vivekanand Jha, Richard Lafayette

Get full text

WCN24-1688 SELF-REPORTED QUALITY OF LIFE IN COMPLEMENT 3 GLOMERULOPATHY PATIENTS DELINEATED BY CKD STAGE: A REAL-WORLD, MULTI-COUNTRY SURVEY by Richard Lafayette, Raisa Sidhu, Clare Proudfoot, Katharina Pannagl, Briana Ndife, Serge Smeets, Kathleen Murphy, Raymond Przybysz, Jonathan de Courcy, Susanna Libby, Smeeta Sinha

Get full text

WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL by Jonathan Barratt, Richard Lafayette, Hitoshi Suzuki, Sreelatha Melamadothil, Laura Kooeinga, Chula Herath, Muh Geot Wong, David Oldach, Asher Schachter, Mohit Mathur, Yusuke Suzuki

Get full text

WCN25-844 FELZARTAMAB FOR IgA NEPHROPATHY: FINAL RESULTS OF THE IGNAZ STUDY by Uptal Patel, Jürgen Flöge, Jonathan Barratt, Richard Lafayette, Brian Schwartz, Paul Manser, Lisa Kivman, Stefan Ha¨rtle, Nicola Faulhaber, Anjali Thakur, Sean Barbour

Get full text

WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

Get full text

WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL by Richard Lafayette, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Jonathan Barratt

Get full text

WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

Get full text

WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

Get full text

WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ATACICEPT VS PLACEBO ON PROTEINURIA AND RENAL FUNCTION PRESERVATION IN IGA NEPHROPATHY by Jonathan Barratt, Bart Maes, Rubeen Israni, Xuelian Wei, Jürgen Floege, Vivekanand Jha, Vladimir Tesar, Hong Zhang, Sean Barbour, Hitoshi Suzuki, Hernan Trimarchi, Celia Lin, Richard Lafayette

Get full text

WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN by Vivekanand Jha, Richard Lafayette, Sean Barbour, Robert Brenner, Kerry Cooper, Xuelian Wei, Necmi Eren, Jürgen Floege, Sung Gyun Kim, Bart Maes, Richard Phoon, Harmeet Singh, Vladimír Tesař, Jonathan Barratt

Get full text

WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY by Richard Lafayette, Hernan Trimarchi, Jonathan Barratt, Kevin Carroll, Vladimír Tesar, Hong Zhang, Yusuke Suzuki, Adrian Liew, Muh Geot Wong, Lokesh Shah, Jing Xia, Cecile Fajaro, Jeffrey Hafkin, Vlado Perkovic

Get full text

Erratum to “Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1283-1287]... by Sean J. Barbour, Rosanna Coppo, Jonathan Barratt, Lee Er, Richard Lafayette, Hiddo J.L. Heerspink, Dana V. Rizk, Adrian Liew, Vivekanand Jha, Hong Zhang, Yusuke Suzuki, Hernan Trimarchi, Daniel C. Cattran

Get full text

Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts by Sean J. Barbour, Rosanna Coppo, Jonathan Barratt, Lee Er, Richard Lafayette, Hiddo J.L. Heerspink, Dana V. Rizk, Adrian Liew, Vivekanand Jha, Hong Zhang, Yusuke Suzuki, Hernan Trimarchi, Daniel C. Cattran

Get full text